Latest AstraZeneca Stories
GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed) Unit. Clostridium difficile infections are the leading cause of hospital-acquired bacterial infections in the...
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2012 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA). OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD),...
CHICAGO, Dec. 12, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Myriad Genetics Inc. (Nasdaq:MYGN), Sanofi (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NYSE:AZN). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)...
CARLSBAD, Calif., Dec. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3(Rx), a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas. Antisense therapies target the proteins involved in disease processes...
Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the University of Oxford recently revealed a study which showed that prolonged use of tamoxifen could help breast cancer from returning. Tamoxifen has been used in the past as daily treatment for female patients with breast cancer in remission. The study could impact the current recommendations for the treatment, which is five years for female patients. The findings of the study were recently revealed at the annual...
PITTSBURGH, Dec. 5, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 16/12.5 mg, 32/12.5 mg and 32/25 mg. This product is the generic version of AstraZeneca's Atacand HCT(®), and is indicated for the treatment of hypertension. This fixed...
BASEL, Switzerland, Dec. 4, 2012 /PRNewswire/ -- Syngenta announced today that results from expanded US field trials in 2012 have confirmed that corn hybrids with the Agrisure Artesian(TM) native trait outperform comparable hybrids. An average yield advantage of around 17 percent was observed across severe and extreme drought conditions. In areas of severe drought stress, Agrisure Artesian hybrids increased yields by 12 percent. The yield gain in extreme drought conditions...
College football and basketball games may provide more than a way for students to show school spirit – they could help prevent the flu. According to a new study by researchers at Wake Forest Baptist Medical Center, colleges and universities should implement new or improved influenza vaccine strategies, such as giving flu shots at sporting events or during campus-wide, day-long campaigns, to increase the number of their students who get the annual flu vaccine. In the early online...
JERSEY CITY, N.J., Dec. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in South America, including Brazil, Central America, Mexico and the Caribbean. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Under the terms of the agreement AstraZeneca is responsible for the...
WELWYN GARDEN CITY, England and BOSTON, November 30, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, is delighted to announce that its Chief Scientific Officer and founder, Fiona Marshall, has received a 2012 Women of Outstanding Achievement Award from WISE, a UK national campaign to promote female talent in science, engineering, technology and the built environment. Dr Marshall received the award in the Innovation and Entrepreneurship...
